nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

07.04.2020 | Review – Cancer Research

Signaling pathways and clinical application of RASSF1A and SHOX2 in lung cancer

verfasst von: Nanhong Li, Yu Zeng, Jian Huang

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

An increasing number of studies have focused on the early diagnostic value of the methylation of RASSF1A and SHOX2 in lung cancer. However, the intricate cellular events related to RASSF1A and SHOX2 in lung cancer are still a mystery. For researchers and clinicians aiming to more profoundly understand the diagnostic value of methylated RASSF1A and SHOX2 in lung cancer, this review will provide deeper insights into the molecular events of RASSF1A and SHOX2 in lung cancer.

Methodology

We searched for relevant publications in the PubMed and Google Scholar databases using the keywords “RASSF1A”, “SHOX2” and “lung cancer” etc. First, we reviewed the RASSF1A and SHOX2 genes, from their family structures to the functions of their basic structural domains. Then we mainly focused on the roles of RASSF1A and SHOX2 in lung cancer, especially on their molecular events in recent decades. Finally, we compared the value of measuring RASSF1A and SHOX2 gene methylation with that of the common methods for the diagnosis of lung cancer patients.

Results

The RASSF1A and SHOX2 genes were confirmed to be regulators or effectors of multiple cancer signaling pathways, driving tumorigenesis and lung cancer progression. The detection of RASSF1A and SHOX2 gene methylation has higher sensitivity and specificity than other commonly used methods for diagnosing lung cancer, especially in the early stage.

Conclusions

The RASSF1A and SHOX2 genes are critical for the processes of tumorigenesis, development, metastasis, drug resistance, and recurrence in lung cancer. The combined detection of RASSF1A and SHOX2 gene methylation was identified as an excellent method for the screening and surveillance of lung cancer that exhibits high sensitivity and specificity.

Abu-Remaileh M et al (2015) Chronic inflammation induces a novel epigenetic program that is conserved in intestinal adenomas and in colorectal cancer. Cancer Res 75:2120–2130. https://doi.org/10.1158/0008-5472.CAN-14-3295 CrossRefPubMed

Alanazi IO, AlYahya SA, Ebrahimie E, Mohammadi-Dehcheshmeh M (2018) Computational systems biology analysis of biomarkers in lung cancer; unravelling genomic regions which frequently encode biomarkers, enriched pathways, and new candidates. Gene 659:29–36. https://doi.org/10.1016/j.gene.2018.03.038 CrossRefPubMed

Aza-Carmona M et al (2011) SHOX interacts with the chondrogenic transcription factors SOX5 and SOX6 to activate the aggrecan enhancer. Hum Mol Genet 20:1547–1559. https://doi.org/10.1093/hmg/ddr032 CrossRefPubMed

Aza-Carmona M et al (2014) NPPB and ACAN, two novel SHOX2 transcription targets implicated in skeletal development. PLoS ONE 9:e83104. https://doi.org/10.1371/journal.pone.0083104 CrossRefPubMedPubMedCentral

Balek L et al (2018) Proteomic analyses of signalling complexes associated with receptor tyrosine kinase identify novel members of fibroblast growth factor receptor 3 interactome. Cell Signal 42:144–154. https://doi.org/10.1016/j.cellsig.2017.10.003 CrossRefPubMed

Baniwal SK et al (2010) Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis. Mol Cancer 9:258. https://doi.org/10.1186/1476-4598-9-258 CrossRefPubMedPubMedCentral

Bao Y, Liu X, Liu Y, Wang S, Wu B (2019) Ras-association domain family 1 (RASSF1A) gene regulates progression, migration and invasion of bladder cancer. Surg Oncol Oxf 30:63–71CrossRef

Baubec T et al (2015) Genomic profiling of DNA methyltransferases reveals a role for DNMT3B in genic methylation. Nature 520:243–247. https://doi.org/10.1038/nature14176 CrossRefPubMed

Bi L et al (2018) A novel miR-375-HOXB3-CDCA3/DNMT3B regulatory circuitry contributes to leukemogenesis in acute myeloid leukemia. BMC Cancer 18:182. https://doi.org/10.1186/s12885-018-4097-z CrossRefPubMedPubMedCentral

Blaschke RJ et al (1998) SHOT, a SHOX-related homeobox gene, is implicated in craniofacial, brain, heart, and limb development. Proc Natl Acad Sci USA 95:2406–2411CrossRef

Blumenthal GM et al (2018) Current status and future perspectives on neoadjuvant therapy in lung cancer. J Thorac Oncol 13:1818–1831. https://doi.org/10.1016/j.jtho.2018.09.017 CrossRefPubMed

Bobick BE, Cobb J (2012) Shox2 regulates progression through chondrogenesis in the mouse proximal limb. J Cell Sci 125:6071–6083. https://doi.org/10.1242/jcs.111997 CrossRefPubMed

Bonafe L et al (2015) Nosology and classification of genetic skeletal disorders: 2015 revision. Am J Med Genet A 167A:2869–2892. https://doi.org/10.1002/ajmg.a.37365 CrossRefPubMed

Boncinelli E (1997) Homeobox genes and disease. Curr Opin Genet Dev 7:331–337. https://doi.org/10.1016/s0959-437x(97)80146-3 CrossRefPubMed

Braconi C, Huang N, Patel T (2010) MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology 51:881–890. https://doi.org/10.1002/hep.23381 CrossRefPubMedPubMedCentral

Bräuer-Hartmann D et al (2015) PML/RARα-regulated miR-181a/b cluster targets the tumor suppressor RASSF1A in acute promyelocytic leukemia. Cancer Res 75:3411–3424CrossRef

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492 CrossRef

Burbee DG et al (2001) Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 93:691–699CrossRef

Byun D, Lee M, Chae KS, Ryu B, Chi SJCR (2001) Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric. Adenocarcinoma 61:7034–7038

Chen T, Sun Z, Liu F, Wang Q (2017) RASSF1A and SIRT6 in non-small cell lung cancer: Relationship with clinical outcome. Oncol Lett 14:5759–5764. https://doi.org/10.3892/ol.2017.6172 CrossRefPubMedPubMedCentral

Chu X, Hou X, Song W, Xue Z, Wang B, Zhang LJCB, Therapy (2011) Diagnostic values of SCC, CEA, Cyfra21–1 and NSE for lung cancer in patients with suspicious pulmonary masses: a single center analysis 11:995–1000

Clement-Jones M et al (2000) The short stature homeobox gene SHOX is involved in skeletal abnormalities in turner syndrome. Hum Mol Genet 9:695–702CrossRef

Dabral S et al (2019) A RASSF1A-HIF1alpha loop drives Warburg effect in cancer and pulmonary hypertension. Nat Commun 10:2130. https://doi.org/10.1038/s41467-019-10044-z CrossRefPubMedPubMedCentral

Dalle Carbonare L, Innamorati G, Valenti MT (2012) Transcription factor Runx2 and its application to bone tissue engineering. Stem Cell Rev Rep 8:891–897. https://doi.org/10.1007/s12015-011-9337-4 CrossRefPubMed

Darwiche K et al (2013) Assessment of SHOX2 methylation in EBUS-TBNA specimen improves accuracy in lung cancer staging. Ann Oncol 24:2866–2870CrossRef

Deans CA, Maggert KAJG (2015) What do you mean, “Epigenetic”? 199:887–896

Dela Cruz CS, Tanoue LT, Matthay RA (2011) Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med 32:605–644. https://doi.org/10.1016/j.ccm.2011.09.001 CrossRefPubMed

De Baere E, Speleman F, Van Roy N, De Paepe A, Messiaen LJC, Research G (1998) Assignment of SHOX2 (alias OG12X and SHOT) to human chromosome bands 3q25 -%3e q26.1 by in situ hybridization 82:228–229

De Fraipont F et al (2012) An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002. Trial 18:2976–2986

Donninger H, Vos MD, Clark GJ (2007) The RASSF1A tumor suppressor. J Cell Sci 120:3163–3172. https://doi.org/10.1242/jcs.010389 CrossRefPubMed

Donninger H, Schmidt ML, Mezzanotte J, Barnoud T, Clark GJ (2016) Ras signaling through RASSF proteins. Semin Cell Dev Biol 58:86–95. https://doi.org/10.1016/j.semcdb.2016.06.007 CrossRefPubMedPubMedCentral

Dubois F et al. (2016) RASSF1A Suppresses the Invasion and metastatic potential of human non–small cell lung cancer cells by inhibiting YAP activation through the GEF-H1/RhoB pathway 76:1627–1640

Dubois F et al (2019) Role of the YAP-1 transcriptional target cIAP2 in the differential susceptibility to chemotherapy of non-small-cell lung cancer (NSCLC) patients with tumor RASSF1A gene methylation from the phase 3 IFCT-0002 trial. Cancers (Basel). https://doi.org/10.3390/cancers11121835 CrossRef

Dubois F, Bergot E, Levallet G (2019) Cancer and RASSF1A/RASSF1C, the two faces of Janus. Trends Cancer 5:662–665. https://doi.org/10.1016/j.trecan.2019.10.001 CrossRefPubMed

Duruisseaux M (2017) Esteller MJSiCB. Lung cancer epigenetics: From knowledge to applications 51:116–128

Duymich CE, Charlet J, Yang X, Jones PA, Liang G (2016) DNMT3B isoforms without catalytic activity stimulate gene body methylation as accessory proteins in somatic cells. Nat Commun 7:11453. https://doi.org/10.1038/ncomms11453 CrossRefPubMedPubMedCentral

Esteller MJO (2002) CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future 21:5427–5440

Feng H, Zhang Z, Qing X, Wang X, Liang C, Liu DJE, Pathology M (2016) Promoter methylation of APC and RAR-β genes as prognostic markers in non-small cell lung cancer (NSCLC). EXP Mol Biol 100:109–113

Feng M, Yang X, Ma Q, He YJM (2017) Retrospective analysis for the false positive diagnosis of PET-CT scan in lung cancer patients 96

Fernandes MS, Carneiro F, Oliveira C, Seruca R (2013) Colorectal cancer and RASSF family–a special emphasis on RASSF1A. Int J Cancer 132:251–258. https://doi.org/10.1002/ijc.27696 CrossRefPubMed

Foran E, Garrity-Park MM, Mureau C, Newell J, Smyrk TC, Limburg PJ, Egan LJ (2010) Upregulation of DNA methyltransferase-mediated gene silencing, anchorage-independent growth, and migration of colon cancer cells by interleukin-6. Mol Cancer Res 8:471–481. https://doi.org/10.1158/1541-7786.MCR-09-0496 CrossRefPubMed

Gagliardi M, Strazzullo M, Matarazzo MR (2018) DNMT3B functions: novel insights from human disease. Front Cell Dev Biol 6:140. https://doi.org/10.3389/fcell.2018.00140 CrossRefPubMedPubMedCentral

Gehring WJ, Affolter M, Burglin T (1994) Homeodomain proteins. Annu Rev Biochem 63:487–526. https://doi.org/10.1146/annurev.bi.63.070194.002415 CrossRefPubMed

Gordon M et al. (2013) The tumor suppressor gene, RASSF1A, is essential for protection against inflammation-induced injury. PloS one 8

Grawenda A, O'neill E (2015) Clinical utility of RASSF1A methylation in human malignancies. Br J Ccancer 113:372–381CrossRef

Heyn H, Esteller M (2012) DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet 13:679–692. https://doi.org/10.1038/nrg3270 CrossRefPubMed

Hong S et al (2014) SHOX2 is a direct miR-375 target and a novel epithelial-to-mesenchymal transition inducer in breast cancer cells. Neoplasia 16(279–290):e275

Hristov G, Marttila T, Durand C, Niesler B, Rappold G, Marchini AJHMG (2014) SHOX triggers the lysosomal pathway of apoptosis via oxidative. Stress 23:1619–1630

Hsu YL, Huang MS, Yang CJ, Hung JY, Wu LY, Kuo PL (2011) Lung tumor-associated osteoblast-derived bone morphogenetic protein-2 increased epithelial-to-mesenchymal transition of cancer by Runx2/Snail signaling pathway. J Biol Chem 286:37335–37346. https://doi.org/10.1074/jbc.M111.256156 CrossRefPubMedPubMedCentral

Hu W, Xin Y, Zhao Y, Hu J (2018) Shox2: the role in differentiation and development of cardiac conduction system Tohoku. J Exp Med 244:177–186. https://doi.org/10.1620/tjem.244.177 CrossRef

Huang X et al (2016) Decitabine and 5-azacitidine both alleviate LPS induced ARDS through anti-inflammatory/antioxidant activity and protection of glycocalyx and inhibition of MAPK pathways in mice. Biomed Pharmacother 84:447–453. https://doi.org/10.1016/j.biopha.2016.09.072 CrossRefPubMed

Huang J, Chen YX, Zhang B (2019) IGF2-AS affects the prognosis and metastasis of gastric adenocarcinoma via acting as a ceRNA of miR-503 to regulate SHOX2. Gastric Cancer. https://doi.org/10.1007/s10120-019-00976-2 CrossRefPubMed

Huang J et al (2019) Enhanced osteopontin splicing regulated by RUNX2 is HDAC-dependent and induces invasive phenotypes in NSCLC cells. Cancer Cell Int 19:306. https://doi.org/10.1186/s12935-019-1033-5 CrossRefPubMedPubMedCentral

Ilse P, Biesterfeld S, Pomjanski N, Wrobel C, Schramm MJCG, Proteomics (2014) Analysis of SHOX2 methylation as an aid to cytology in lung cancer. Diagnosis 11:251–258

Ionta V, Liang W, Kim EH, Rafie R, Giacomello A, Marban E, Cho HC (2015) SHOX2 overexpression favors differentiation of embryonic stem cells into cardiac pacemaker cells, improving biological pacing ability. Stem Cell Rep 4:129–142. https://doi.org/10.1016/j.stemcr.2014.11.004 CrossRef

Iwasa H, Hossain S, Hata Y (2018) Tumor suppressor C-RASSF proteins. Cell Mol Life Sci 75:1773–1787. https://doi.org/10.1007/s00018-018-2756-5 CrossRefPubMed

Johnson JE et al (2007) Differential membrane binding and diacylglycerol recognition by C1 domains of RasGRPs. Biochem J 406:223–236. https://doi.org/10.1042/BJ20070294 CrossRefPubMedPubMedCentral

Kang W et al (2018) miR-375 is involved in Hippo pathway by targeting YAP1/TEAD4-CTGF axis in gastric carcinogenesis. Cell Death Dis 9:92. https://doi.org/10.1038/s41419-017-0134-0 CrossRefPubMedPubMedCentral

Keller M et al (2019) NDR2 kinase contributes to cell invasion and cytokinesis defects induced by the inactivation of RASSF1A tumor-suppressor gene in lung cancer cells. J Exp Clin Cancer Res 38:158. https://doi.org/10.1186/s13046-019-1145-8 CrossRefPubMedPubMedCentral

Kilili GK, Kyriakis JMJJBC (2010) Mammalian Ste20-like kinase (Mst2) indirectly supports Raf-1/ERK pathway activity Via maintenance of protein phosphatase-2A catalytic subunit levels and consequent suppression of inhibitory Raf-1. Phosphorylation 285:15076–15087

Kneip C et al (2011) SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma 6:1632–1638

Koyama S et al (2016) STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment. Cancer Res 76:999–1008. https://doi.org/10.1158/0008-5472.CAN-15-1439 CrossRefPubMedPubMedCentral

Laird PW (2003) The power and the promise of DNA methylation markers. Nat Rev Cancer 3:253–266. https://doi.org/10.1038/nrc1045 CrossRefPubMed

Lee MG et al (2016) RASSF1A directly antagonizes RhoA activity through the assembly of a Smurf1-mediated destruction complex to suppress tumorigenesis. Cancer Res 76:1847–1859. https://doi.org/10.1158/0008-5472.CAN-15-1752 CrossRefPubMed

Leiro V, De Chiara L, Rodriguez-Girondo M, Botana-Rial M, Valverde D, Nunez-Delgado M, Fernandez-Villar A (2019) Methylation assessment for the prediction of malignancy in mediastinal adenopathies obtained by endobronchial ultrasound-guided transbronchial needle aspiration in patients with lung cancer. Cancers (Basel). https://doi.org/10.3390/cancers11101408 CrossRef

Li Q, Zhu F, Chen PJB, Communications BR (2012) miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting HoxB3 in breast. Cancer 424:28–33

Li L et al (2018) Epigenomic characterization of a p53-regulated 3p22.2 tumor suppressor that inhibits STAT3 phosphorylation via protein docking and is frequently methylated in esophageal and other. Carcinomas 8:61–77

Liao A, Tan G, Chen L, Zhou W, Hu HJO (2016) RASSF1A inhibits gastric cancer cell proliferation by miR-711- mediated downregulation of CDK4 expression 7:5842–5851

Licchesi JD, Westra WH, Hooker CM, Herman JG (2008) Promoter hypermethylation of hallmark cancer genes in atypical adenomatous hyperplasia of the lung. Clin Cancer Res 14:2570–2578. https://doi.org/10.1158/1078-0432.CCR-07-2033 CrossRefPubMed

Lin JJ, Shaw AT (2016) Resisting resistance: targeted therapies in lung cancer trends. Cancer 2:350–364. https://doi.org/10.1016/j.trecan.2016.05.010 CrossRef

Lucic I, Truebestein L, Leonard TA (2016) Novel features of DAG-activated PKC isozymes reveal a conserved 3-D architecture. J Mol Biol 428:121–141. https://doi.org/10.1016/j.jmb.2015.11.001 CrossRefPubMed

Malpeli G et al (2019) Methylation dynamics of RASSF1A and its impact on cancer. Cancers 11:959CrossRef

Marchini A, Ogata T, Rappold GA (2016) A track record on SHOX: from basic research to complex models and therapy. Endocr Rev 37:417–448CrossRef

Markopoulos GS, Roupakia E, Marcu KB, Kolettas E (2019) Epigenetic regulation of inflammatory cytokine-induced epithelial-to-mesenchymal cell transition and cancer. Stem Cell Gen Cell. https://doi.org/10.3390/cells8101143 CrossRef

Mcwilliams A et al (2013) Probability of cancer in pulmonary nodules detected on first screening CT. Cancer 369:910–919

Mehta A, Dobersch S, Romero-Olmedo AJ, Barreto G (2015) Epigenetics in lung cancer diagnosis and therapy. Cancer Metastasis Rev 34:229–241. https://doi.org/10.1007/s10555-015-9563-3 CrossRefPubMed

Mortensen KH, Andersen NH, Gravholt CHJER (2012) Cardiovascular phenotype in turner syndrome—integrating cardiology. Gene Endocrinol 33:677–714

Niklinska W, Naumnik W, Sulewska A, Kozłowski M, Pankiewicz W, Milewski R (2009) Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC). Folia histochemica et cytobiologica 47:275–280

Ogushi K et al (2019) DNA Methylation Status of SHOX-Flanking CpG Islands in Healthy Individuals and Short Stature Patients with Pseudoautosomal Copy Number Variations Cytogenetic and genome research 158:56–62PubMed

Oh MH, Lockwood WW (2017) RASSF1A methylation, YAP1 activation and metastasis: a new role for an old foe in lung cancer. J Thoracic Dis 9:1165–1167. https://doi.org/10.21037/jtd.2017.04.16 CrossRef

Ooki A et al (2017) A panel of novel detection and prognostic methylated DNA markers in primary non-small cell lung cancer and serum DNA. Clin Cancer Res 23:7141–7152. https://doi.org/10.1158/1078-0432.CCR-17-1222 CrossRefPubMed

Ortizvega S, Khokhlatchev A, Nedwidek M, Zhang X, Dammann R, Pfeifer GP, Avruch JJO (2002) The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1 21:1381–1390

Ozaki T, Wu D, Sugimoto H, Nagase H, Nakagawara A (2013) Runt-related transcription factor 2 (RUNX2) inhibits p53-dependent apoptosis through the collaboration with HDAC6 in response to DNA damage. Cell Death Dis 4:e610. https://doi.org/10.1038/cddis.2013.127 CrossRefPubMedPubMedCentral

Ozaki T, Yu M, Yin D, Sun D, Zhu Y, Bu Y, Sang M (2018) Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations. BMC Cancer 18:309. https://doi.org/10.1186/s12885-018-4217-9 CrossRefPubMedPubMedCentral

Pallares J et al (2008) Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma. Mod Pathol 21:691–699. https://doi.org/10.1038/modpathol.2008.38 CrossRefPubMed

Pankova D et al (2019) RASSF1A controls tissue stiffness and cancer stem-like cells in lung adenocarcinoma. EMBO J 38:e100532. https://doi.org/10.15252/embj.2018100532 CrossRefPubMedPubMedCentral

Papaspyropoulos A et al (2018) RASSF1A uncouples Wnt from Hippo signalling and promotes YAP mediated differentiation via p73. Nat Commun 9:424. https://doi.org/10.1038/s41467-017-02786-5 CrossRefPubMedPubMedCentral

Pefani DE, Pankova D, Abraham AG, Grawenda AM, Vlahov N, Scrace SEON (2016) TGF-beta targets the hippo pathway scaffold RASSF1A to facilitate YAP/SMAD2 nuclear translocation. Mol Cell 63:156–166. https://doi.org/10.1016/j.molcel.2016.05.012 CrossRefPubMed

Peng X, Liu X, Xu L, Li Y, Wang H, Song L, Xiao W (2019) The mSHOX2 is capable of assessing the therapeutic effect and predicting the prognosis of stage IV lung cancer. J Thoracic Dis 11:2458CrossRef

Puskaric S et al (2010) Shox2 mediates Tbx5 activity by regulating Bmp4 in the pacemaker region of the developing heart. Hum Mol Genet 19:4625–4633. https://doi.org/10.1093/hmg/ddq393 CrossRefPubMedPubMedCentral

Qu Z, Sun F, Zhou J, Li L, Shapiro SD, Xiao G (2015) Interleukin-6 prevents the initiation but enhances the progression of lung cancer. Cancer Res 75:3209–3215. https://doi.org/10.1158/0008-5472.CAN-14-3042 CrossRefPubMedPubMedCentral

Ram R, Mendiratta S, Bodemann BO, Torres MJ, Eskiocak U, White MAJM, Biology C (2014) RASSF1A inactivation unleashes a tumor suppressor/oncogene cascade with context-dependent consequences on cell cycle progression 34:2350–2358

Ren M, Wang C, Sheng D, Shi Y, Jin M, Xu S (2017) Methylation analysis of SHOX2 and RASSF1A in bronchoalveolar lavage fluid for early lung cancer diagnosis. Ann Diagn Pathol 27:57–61CrossRef

Richter AM, Pfeifer GP, Dammann RH (2009) The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta 1796:114–128. https://doi.org/10.1016/j.bbcan.2009.03.004 CrossRefPubMed

Robertson KD (2005) DNA methylation and human disease. Nat Rev Genet 6:597–610. https://doi.org/10.1038/nrg1655 CrossRefPubMed

Romano D, Nguyen LK, Matallanas D, Halasz M, Doherty C, Kholodenko BN, Kolch W (2014) Protein interaction switches coordinate Raf-1 and MST2/Hippo signalling. Nat Cell Biol 16:673–684. https://doi.org/10.1038/ncb2986 CrossRefPubMed

Rosin JM, McAllister BB, Dyck RH, Percival CJ, Kurrasch DM, Cobb J (2015) Mice lacking the transcription factor SHOX2 display impaired cerebellar development and deficits in motor coordination. Dev Biol 399:54–67. https://doi.org/10.1016/j.ydbio.2014.12.013 CrossRefPubMed

Rovescalli A, Asoh S, Nirenberg MW (1996) Cloning and characterization of four murine homeobox genes. Proc Natl Acad Sci USA 93:10691–10696CrossRef

Sawada R, Kamei H, Hakuno F, Takahashi S, Shimizu TJDD (2015) In vivo loss of function study reveals the short stature homeobox-containing (shox) gene plays indispensable roles in early embryonic growth and bone formation in zebrafish 244:146–156

Schmidt B, Beyer J, Dietrich D, Bork I, Liebenberg V, Fleischhacker M (2015) Quantification of cell-free mSHOX2 plasma DNA for therapy monitoring in advanced stage non-small cell (NSCLC) and small-cell lung cancer (SCLC) patients. PLoS One 10

Schmidt ML, Hobbing KR, Donninger H, Clark GJ (2018) RASSF1A deficiency enhances RAS-driven lung tumorigenesis. Cancer Res 78:2614–2623. https://doi.org/10.1158/0008-5472.CAN-17-2466 CrossRefPubMedPubMedCentral

Schneider KU et al (2011) Correlation of SHOX2 gene amplification and DNA methylation in lung cancer. Tumors 11:102–102

Semina EV, Reiter RS, Murray JCJHMG (1998) A new human homeobox gene OGI2X is a member of the most conserved homeobox gene family and is expressed during heart development in mouse 7:415–422

Sherwood V, Recino A, Jeffries A, Ward A, Chalmers AD (2009) The N-terminal RASSF family: a new group of Ras-association-domain-containing proteins, with emerging links to cancer formation. Biochem J 425:303–311. https://doi.org/10.1042/BJ20091318 CrossRefPubMed

Song L, Yu H, Li Y (2015) Diagnosis of lung cancer by SHOX2 gene methylation assay. Mol Diagn Ther 19:159–167. https://doi.org/10.1007/s40291-015-0144-5 CrossRefPubMed

Strzelak A, Ratajczak A, Adamiec A, Feleszko W (2018) Tobacco smoke induces and alters immune responses in the lung triggering inflammation, allergy, asthma and other lung diseases: a mechanistic review. Int J Environ Res Public Health. https://doi.org/10.3390/ijerph15051033 CrossRefPubMedPubMedCentral

Sun C, Liu XH, Sun YR (2019) MiR-223–3p inhibits proliferation and metastasis of oral squamous cell carcinoma by targeting SHOX2. Eur Rev Med Pharmacol Sci 23:6927–6934. https://doi.org/10.26355/eurrev_201908_18732 CrossRefPubMed

Tan X et al (2013) Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer. PLoS ONE 8:e80885. https://doi.org/10.1371/journal.pone.0080885 CrossRefPubMedPubMedCentral

Thaler S, Hahnel PS, Schad A, Dammann R, Schuler M (2009) RASSF1A mediates p21Cip1/Waf1-dependent cell cycle arrest and senescence through modulation of the Raf-MEK-ERK pathway and inhibition of Akt. Cancer Res 69:1748–1757. https://doi.org/10.1158/0008-5472.CAN-08-1377 CrossRefPubMed

Thaler S, Schmidt M, Schad A, Sleeman JP (2012) RASSF1A inhibits estrogen receptor alpha expression and estrogen-independent signalling: implications for breast cancer development. Oncogene 31:4912–4922. https://doi.org/10.1038/onc.2011.658 CrossRefPubMed

Timp W, Feinberg AP (2013) Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev Cancer 13:497–510. https://doi.org/10.1038/nrc3486 CrossRefPubMedPubMedCentral

Tommasi S, Besaratinia A, Wilczynski SP, Pfeifer GPJO (2011) Loss of Rassf1a enhances p53-mediated tumor predisposition and accelerates progression to aneuploidy 30:690–700

Van Schaick HSA et al. (1997) Homeobox gene Prx3 expression in rodent brain and extraneural tissues 94:12993–12998

Valenti MT, Serafini P, Innamorati G, Gili A, Cheri S, Bassi C, Dalle Carbonare L (2016) Runx2 expression: a mesenchymal stem marker for cancer. Oncol Lett 12:4167–4172. https://doi.org/10.3892/ol.2016.5182 CrossRefPubMedPubMedCentral

Volodko N, Gordon M, Salla M, Ghazaleh HA, Baksh S (2014) RASSF tumor suppressor gene family: biological functions and regulation. FEBS Lett 588:2671–2684. https://doi.org/10.1016/j.febslet.2014.02.041 CrossRefPubMed

Volodko N et al (2016) RASSF1A site-specific methylation hotspots in cancer and correlation with RASSF1C and MOAP-1. Cancers (Basel). https://doi.org/10.3390/cancers8060055 CrossRef

Vos MD et al (2006) The RASSF1A tumor suppressor activates Bax via MOAP-1. J Biol Chem 281:4557–4563. https://doi.org/10.1074/jbc.M512128200 CrossRefPubMed

Wang H et al (2011) MicroRNA-342 inhibits colorectal cancer cell proliferation and invasion by directly targeting DNA methyltransferase 1. Carcinogenesis 32:1033–1042. https://doi.org/10.1093/carcin/bgr081 CrossRefPubMed

Weng Z et al. (1995) Structure-function analysis of SH3 domains: SH3 binding specificity altered by single amino acid substitutions 15:5627–5634

Xie J, Yu F, Li D, Zhu X, Zhang X, Lv Z (2016) MicroRNA-218 regulates cisplatin (DPP) chemosensitivity in non-small cell lung cancer by targeting RUNX2. Tumour Biol 37:1197–1204. https://doi.org/10.1007/s13277-015-3831-2 CrossRefPubMed

Yang L, Ma Z, Wang D, Zhao W, Chen L, Wang G (2010) MicroRNA-602 regulating tumor suppressive gene RASSF1A is overexpressed in hepatitis B virus-infected liver and hepatocellular carcinoma. Cancer Biol Ther 9:803–808. https://doi.org/10.4161/cbt.9.10.11440 CrossRefPubMed

Yang T et al (2013) Elevated SHOX2 expression is associated with tumor recurrence of hepatocellular carcinoma. Ann Surg Oncol 20:644–649CrossRef

Yang X, Han H, De Carvalho DD, Lay FD, Jones PA, Liang G (2014) Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell 26:577–590. https://doi.org/10.1016/j.ccr.2014.07.028 CrossRefPubMedPubMedCentral

Yang L et al (2015) Mutations of p53 and KRAS activate NF-kappaB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells. Cancer Lett 357:520–526. https://doi.org/10.1016/j.canlet.2014.12.003 CrossRefPubMed

Yi J, Jin L, Chen J, Feng B, He Z, Chen L, Song H (2017) MiR-375 suppresses invasion and metastasis by direct targeting of SHOX2 in esophageal squamous cell carcinoma. Acta Biochim Biophys Sin (Shanghai) 49:159–169. https://doi.org/10.1093/abbs/gmw131 CrossRef

Yi M et al (2018) Dual-functionality of RASSF1A overexpression in A375 cells is mediated by activation of IL-6/STAT3 regulatory loop. Mol Biol Rep 45:1277–1287. https://doi.org/10.1007/s11033-018-4288-3 CrossRefPubMed

Yu L, Liu H, Yan M, Yang J, Long F, Muneoka K, Chen Y (2007) Shox2 is required for chondrocyte proliferation and maturation in proximal limb skeleton. Dev Biol 306:549–559. https://doi.org/10.1016/j.ydbio.2007.03.518 CrossRefPubMedPubMedCentral

Yu J et al (2018) MicroRNA181a promotes cell proliferation and inhibits apoptosis in gastric cancer by targeting RASSF1A. Oncol Rep 40:1959–1970. https://doi.org/10.3892/or.2018.6632 CrossRefPubMedPubMedCentral

Zhang X et al (2015a) Runx2-Smad signaling impacts the progression of tumor-induced bone disease. Int J Cancer 136:1321–1332. https://doi.org/10.1002/ijc.29094 CrossRefPubMed

Zhang X et al (2015b) Expression of the IL-11 gene in metastatic cells is supported by Runx2-Smad and Runx2-cJun complexes induced by TGFbeta1. J Cell Biochem 116:2098–2108. https://doi.org/10.1002/jcb.25167 CrossRefPubMedPubMedCentral

Zhang C et al (2017) DNA methylation analysis of the SHOX2 and RASSF1A panel in bronchoalveolar lavage fluid for lung cancer diagnosis. J Cancer 8:3585CrossRef

Zhang Z, Yan S, Cui H, Chen H, Liu JJMSM (2019) Correlation BETWEEN RASSF1A gene promoter hypermethylation in serum or sputum and non-small cell lung cancer (NSCLC): a meta-analysis 25:5518–5524

Zhao Q et al (2015) Diagnostic value of SHOX2 DNA methylation in lung cancer: a meta-analysis 8:3433–3439

Zhu KW, Liu Q, Zhou Y, Tao C, Zhao Z, Sun J, Xu HJBG (2015) Oncogenes and tumor suppressor genes: comparative genomics and network perspectives 16:1–11

Titel: Signaling pathways and clinical application of RASSF1A and SHOX2 in lung cancer
verfasst von: Nanhong Li
Yu Zeng
Jian Huang
Publikationsdatum: 07.04.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 6/2020
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-020-03188-9

Springer Medizin

Signaling pathways and clinical application of RASSF1A and SHOX2 in lung cancer

Abstract

Background

Methodology

Results

Conclusions

Neu im Fachgebiet Onkologie

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

Update Onkologie

Springer Medizin

Abstract

Background

Methodology

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2020

Can robotic-assisted radical cystectomy provide patients with a smaller trauma and faster recovery period? A systematic review and meta-analysis of comparative trials

Pregnancy, time to pregnancy and obstetric outcomes among female childhood cancer survivors: results of the DCOG LATER-VEVO study

Attitude of cancer patients from online self-help groups towards physical activity

Proton therapy re-irradiation preserves health-related quality of life in large recurrent glioblastoma

Comparison of outcomes following segmentectomy or lobectomy for patients with clinical N0 invasive lung adenocarcinoma of 2 cm or less in diameter

High MICB expression as a biomarker for good prognosis of colorectal cancer

Neu im Fachgebiet Onkologie

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

Update Onkologie